Browsing Category
Pharma Industry News
4724 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Zydus Lifesciences (NSE: Zyduslife) secures FDA approval for ammonium lactate cream as U.S. generics execution deepens
Zydus Lifesciences Limited secures USFDA approval for ammonium lactate cream. Find out why this modest launch matters for U.S. generics strategy.
Nektar Therapeutics (NASDAQ: NKTR) raises $460m as rezpegaldesleukin data strengthens Phase 3 autoimmune outlook
Nektar Therapeutics raised $460 million after strong rezpegaldesleukin data. Find out what this means for Phase 3 trials and autoimmune drug markets.
Are oral GLP-1 pills finally closing the credibility gap with injectables after ribupatide data
Are oral GLP-1 and GIP agonists becoming viable after ribupatide’s Phase 2 data? Explore what this shift means for obesity drug strategy.
How American Glaucoma Society data may shape NCX 470’s clinical and commercial future
Find out how Nicox SA’s NCX 470 data at the American Glaucoma Society could influence regulatory approval and glaucoma market adoption.
Is GPCR immuno-oncology ready for prime time as Kainova Therapeutics advances DT-7012
Explore how Kainova Therapeutics’ DT-7012 program could reshape GPCR immuno-oncology and what it signals for investors and competitors.
How a 48-channel SPR system from Carterra Inc. could change hit identification strategies across pharma pipelines
Find out how Carterra Inc.’s 48-channel SPR system could change early hit identification and discovery economics across pharma pipelines.
Is photodynamic therapy ready to move beyond facial use in actinic keratosis care?
Biofrontera Inc.’s Phase 3 Ameluz data extend photodynamic therapy beyond the face. Find out how this could reshape field treatment decisions.
Amgen (NASDAQ: AMGN) wins EC approval for UPLIZNA in generalized myasthenia gravis market
European Commission clears Amgen Inc.’s UPLIZNA for generalized myasthenia gravis. Discover what this means for competition, pricing, and the autoimmune drug market.
Lilly (NYSE: LLY) to acquire Orna Therapeutics for $2.4bn to expand in vivo CAR-T strategy
Eli Lilly and Company (LLY) to acquire Orna Therapeutics for up to $2.4B. Explore how in vivo CAR-T and circular RNA may transform autoimmune therapy.
Avacta Therapeutics (AIM: AVCT) elevates Francis Wilson to CSO as faridoxorubicin dosing cap is removed
Avacta Therapeutics lifts AVA6000 dosing cap and appoints a new Chief Scientific Officer. Explore what this means for pre|CISION and investors.